THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis.
"I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, including leading the commercialization of the world's leading heart failure drug and building out a strong, multiple-product cardiometabolic business during his time at Novartis. His experience in the pharmaceutical industry spans research, development, commercialization and the evaluation and negotiation of strategic acquisitions, licensing and partnerships. We believe that adding Mike's leadership and complementary capabilities and experience to those of our talented existing management team will position the company for tremendous future success."
"I am excited and honored to be appointed Lexicon's new chief executive officer," said Dr. Exton. "I am impressed with Lexicon's current assets and pipeline and look forward to leading this talented group of employees as we focus on executing together on the important near-term objectives to drive value for the future."
Dr. Exton's broad experience ...